Cannabis Hyperemesis Syndrome Class Action Certified

*TORONTO –* Thousands of Canadian cannabis users are hospitalized and
diagnosed with Cannabinoid Hyperemesis Syndrome (CHS) every year. CHS is a
dangerous side effect that can develop from the regular use of cannabis
products. CHS involves cyclical bouts of severe nausea, vomiting, and
abdominal pain, which can persist for days and can occur as often as once
every five minutes. In extreme cases, CHS can result in organ failure and
even death.

On May 14, 2025, the Ontario Superior Court of Justice certified a national
class action which alleges that Aurora Cannabis Inc. and Aurora Cannabis
Enterprises Inc. negligently failed to warn consumers of the risk of
developing CHS posed by the regular use of their cannabis products. This
means the action can now proceed as a class action. No findings of
liability have been made against the defendants.

The action was commenced by V.T., a Canadian Forces veteran who was
prescribed cannabis to treat medical conditions. V.T. purchased medicinal
cannabis from the defendants and used it as prescribed, until they suffered
two extreme bouts of nausea, vomiting, and abdominal pain that were so
severe V.T. had to be hospitalized. On the second E.R. visit, V.T. was
diagnosed as suffering from CHS. The only certain cure for CHS is to stop
consuming cannabis, which V.T. did, and is now symptom-free. None of the
cannabis products that V.T. consumed contained any warning about CHS, nor
is there any warning in the product monograph or on Aurora’s website.

The claim alleges that the Defendants knew, or should have known, of the
risk of CHS arising from the regular use of their cannabis products, but
negligently failed to provide any warning to consumers or prescribing
physicians about the risk that they could develop CHS. The class action
seeks to recover damages for the Class Members who developed CHS.

The class action is brought on behalf of all persons in Canada who
purchased a Cannabis Product from Aurora Cannabis Inc. or Aurora Cannabis
Enterprises Inc. (which includes MedReleaf) on or after February 1, 2014,
to May 14, 2025, who were diagnosed or differentially diagnosed with CHS
during the period after consuming one or more cannabis products. Cannabis
Products are the cannabis and/or synthetic cannabinoid resins, pills,
lozenges, concentrates, oils, edibles, beverages, vapours, and raw and
adulterated plant material cultivated, designed, manufactured, packaged,
labeled, distributed, marketed, and/or sold by the defendants.

The allegations contained in the Fresh as Amended Statement of Claim have
not been proved in court, and the defendants deny the Plaintiff’s claims.